Two-year Survival Outcomes among Patients with Cholangiocarcinoma Diagnosed during 2010 in Roi-et Province, Thailand
DOI:
https://doi.org/10.59096/osir.v9i3.263210Keywords:
survival, cholangiocarcinoma, prognosis, ThailandAbstract
Cholangiocarcinoma (CCA) is a common cancer in Thailand. This study aimed to describe epidemiological characteristics and survival outcomes of patients diagnosed with CCA at Roi-et Cancer Center during January and December 2010. Cox proportional hazard regression analysis was used to analyze data from 119 patients diagnosed with imaging techniques. The median survival time was found to be 4.4 months and the 2-year survival rate was 14.5%. From multivariate analysis by Cox proportional hazard regression, carcinoembryonic antigen (CEA) level >5 µg/l and alkaline phosphatase (ALP) >150 IU/l were found to be indicators of decreased survival time while having surgery led to longer survival time. To improve survival outcome, early detection through screening program and early diagnosis must be organized. Prognostic values of CEA and ALP should be considered.
References
World Health Organization. Cancer. 2015 Feb [cited 2012 Aug 27]. <http://www.who.int/mediacentre/factsheets/fs297/en/index.html>
World Health Organization. World health statistic 2012. France: World Health Organization. p. 63-84 [cited 2012 Aug 27]. <http://www.who.int/healthinfo/EN_WHS2012_Full.pdf>
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006 May 10;24(14):2137-50.
Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst. 2007 Jun 6;99(11):895-7.
McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int. 2006 Nov;26(9):1047-53.
Cho SY, Park SJ, Kim SH, Han SS, Kim YK, Lee KW, et al. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol. 2010 Jul;17(7):1823-30. Epub 2010 Feb 18.
American Cancer Society. Bile duct cancer (Cholangiocarcinoma). 2012 [cited on 2012 Aug 28]. <http://www.cancer.org/Cancer/BileDuctCancer/DetailedGuide/index>
Attasara P, Buasom R, editors. Cancer registry 2010. Bangkok: Creative Commons; 2011.
Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S, Sumitsawan Y, Attasara P, editors. Cancer in Thailand. Vol IV, 1998-2000. Bangkok: Bangkok Medical Publisher; 2007.
Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S, Sumitsawan Y, Attasara P,
editors. Cancer in Thailand. Vol V, 2001-2003. Bangkok: Bangkok Medical Publisher; 2010.
Jongsuksuntigul P, Imsomboon T. Epidemiology of opisthorchiasis and national control program in Thailand. Southeast Asian J Trop Med Public Health. 1998 Jun;29(2):327-32.
Jongsuksuntigul P, Imsomboon T. Opisthorchiasis control in Thailand. Acta Trop. 2003 Nov;88(3):229-32.
Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S, Parkin DM. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int Health. 2004 May;9(5):588-94.
Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008 May;24(3):349-56.
Yusoff AR, Razak MM, Yoong BK, Vijeyasingam R, Siti ZM. Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia. World J Gastroenterol. 2012 Feb 7;18(5):458-65.
Mihalache F, Tantau M, Diaconu B, Acalovschi M. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis. 2010 Sep;19(3):285-90.
Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang Y, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia. Asian Pac J Cancer Prev. 2010;11(5):1159-66.
Johnson ML, Gordon HS, Petersen NJ, Wray NP, Shroyer AL, Grover FL, et al. Effect of definition of mortality on hospital profiles. Med Care. 2002 Jan;40(1):7-16.
Liu SL, Song ZF, Hu QG, Shan D, Hu SB, Li J, Zheng QC. Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China. 2010 Dec;4(4):457-62. Epub 2010 Nov 16.
Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP, et al. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res. 2010 Aug 20;15(8):357-61.
Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002 Jul;56(1):40-7.
Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg. 1996 Jan;171(1):147-52; discussion 152-3.
Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc. 1993 Sep;68(9):874-9.
Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000 Jan;95(1):204-7.
Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1995 Mar;108(3):865-9.
Björnsson E, Kilander A, Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver. 1999 Dec;19(6):501-8.
Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM. Outcomes after curative resections of cholangiocarcinoma. Arch Surg. 1993 Aug;128(8):871-7.
Khuntikao N. Current concept in management of cholangiocarcinoma. Srinagarind Med J. 2005;20(3):143-9. Thai.
Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004 May;24(2):115-25.
Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005 Oct 8;366(9493):1303-14.
Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012 Dec;61(12):1657-69. Epub 2012 Aug 15.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Outbreak, Surveillance, Investigation & Response (OSIR) Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
